The goal of this study is to learn whether early referral to palliative care improves quality of life for patients with advanced sarcoma.
Participants enrolled in this study will complete quality of life questionnaires before starting their treatment, and every 6 weeks for 24 weeks.
Signed written and voluntary informed consent.
Have histologically documented advanced sarcoma, either locally advanced not amenable to curative treatment, or metastatic.
Age ≥ 18 years.
Have not received any previous systemic treatment with palliative intent for advanced sarcoma.
Clinical evidence of cognitive impairment that would preclude the ability to provide informed consent and complete questionnaires, at investigator´s discretion.
Patient in need of urgent home support services or symptom management through a palliative care team.
Patient is being actively followed by a palliative care physician.
Active psychiatric disorder or drug abuse.
Parallel
Early referral to palliative care
Other interventionParticipant will be referred to palliative care at start of systemic treatment
Standard Treatment
Other interventionParticipants will be referred to palliative care upon appearance of uncontrollable symptoms.
To determine the difference of Health Related Quality of Life (HRQoL) for sarcoma patients who receive early palliative care versus not
HRQoL will be assessed using ESAS-r (Edmonton Symptom Assessment System - revised) and EORTC QLQ-C30 (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire C-30).
Click on the lead sponsor to view all of their trials.
